A reduction of the hematocrit resulted in a normalization of the clot formation kinetics and clot strength in transgenic mice
. | α-Angle . | Maximal amplitude, mm . | Clot lysis, % . | Platelets, 103/μL . | HCT value . |
|---|---|---|---|---|---|
| Tg blood diluted | 58.0 ± 7.6 | 57.5 ± 6.5 | 0.0 ± 0.0 | 732 ± 93 | 0.40 ± 0.01 |
| Tg RBC + wt plasma | 51.9 ± 12.1 | 56.3 ± 5.2 | 1.9 ± 4.3 | 812 ± 316 | 0.42 ± 0.03 |
| Wt blood + hemolysis | 62.3 ± 3.9 | 69.3 ± 1.0 | 0.0 ± 0.0 | 845 ± 16 | 0.42 ± 0.01 |
| Wt 4 mo | 76.3 ± 0.8 | 66.0 ± 6.8 | 0.0 ± 0.0 | 1010 ± 136 | 0.43 ± 0.02 |
| Tg 4 mo | 20.1 ± 5.3* | 35.1 ± 9.1* | 2.1 ± 2.3 | 338 ± 194* | 0.80 ± 0.02* |
. | α-Angle . | Maximal amplitude, mm . | Clot lysis, % . | Platelets, 103/μL . | HCT value . |
|---|---|---|---|---|---|
| Tg blood diluted | 58.0 ± 7.6 | 57.5 ± 6.5 | 0.0 ± 0.0 | 732 ± 93 | 0.40 ± 0.01 |
| Tg RBC + wt plasma | 51.9 ± 12.1 | 56.3 ± 5.2 | 1.9 ± 4.3 | 812 ± 316 | 0.42 ± 0.03 |
| Wt blood + hemolysis | 62.3 ± 3.9 | 69.3 ± 1.0 | 0.0 ± 0.0 | 845 ± 16 | 0.42 ± 0.01 |
| Wt 4 mo | 76.3 ± 0.8 | 66.0 ± 6.8 | 0.0 ± 0.0 | 1010 ± 136 | 0.43 ± 0.02 |
| Tg 4 mo | 20.1 ± 5.3* | 35.1 ± 9.1* | 2.1 ± 2.3 | 338 ± 194* | 0.80 ± 0.02* |
Clot strength (maximal amplitude) and clot kinetics (α-angle) were significantly increased after reduction of hematocrit by addition of plasma to red blood cells. For comparison, values for blood (sampled with sodium-citrate anticoagulation) from 4-month-old wild-type and transgenic mice are shown. Hemolysis (free hemoglobin concentration 3000 mg/L) did not impair the clot formation kinetics and clot strength. Clot lysis (%): 100 — (amplitude [mm] at 30 minutes after maximal amplitude normalized to maximal amplitude [mm] × 100). n = 3-5, except for hemolysis n = 2.
HCT indicates hematocrit; tg, transgenic; RBC, red blood cell; wt, wild-type.
P < .001 compared with all groups.